Neurovance
Built On Experience, Built On Success

Neurovance is led by Chairman and Chief Executive Officer Jeff Bailey, Chief Operating Officer Brian Goff, and Founder and Chief Development Officer Anthony McKinney who are joined by a team of seasoned drug developers.

Members of the management team participated in the development of several neuroscience medications.

Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich.

Neurovance is headquartered in Cambridge, Massachusetts.

Management Team

Jeff Bailey
Chairman and Chief Executive Officer

Mr. Bailey has held executive and leadership positions in the pharmaceutical and diagnostic imaging fields for over 30 years. Recently, he had served as President and Chief Executive Officer of Lantheus Medical Imaging Inc., where he and team launched the IPO. Mr. Bailey had previously served as Chief Operating Officer of Fougera Pharmaceuticals and Chief Commercial Officer for King Pharmaceuticals. He was also President and General Manager of an operating unit team at Novartis Pharmaceuticals. Earlier, he held commercial leadership positions at Johnson & Johnson subsidiary Janssen Pharmaceutica. Additionally, he had extensive supply chain experience at Johnson & Johnson. Mr. Bailey earned a business degree from Rutgers University.

Brian Goff - Neurovance COOBrian Goff
Chief Operating Officer

Mr. Goff brings over 25 years of pharmaceutical leadership experience to Neurovance. Mr. Goff previously was President of the Hematology Division of Baxalta (a 2015 spin-out of Baxter Healthcare). During Mr. Goff’s leadership in that position, he generated significant growth of the hemophilia business and led the launch of several key rare disease products. Prior to joining Baxter in 2012, Mr. Goff was Vice President and Head of Novartis Pharmaceuticals’ multi-billion-dollar Primary Care business. Previously at Novartis’ Swiss headquarters, he led global marketing of their flagship cardiovascular brand, and he spent 14 years in a variety of commercial leadership positions at Johnson & Johnson – including 10 years in CNS disorders.

Mr. Goff was awarded the Healthcare Businesswomen’s Association Mentor of the Year in 2014, and in July, 2016, he was named to the PharmaVoice list of 100 Most Inspiring Leaders in Life Sciences.

He has a BA in Economics from Skidmore College and an M.B.A. from the Wharton School of Business.

Neurovance TeamAnthony McKinney, M.B.A.
Founder and Chief Development Officer

Mr. McKinney began his career at Du Pont Merck with roles in hospital sales, market research and new product planning. He was part of the core team that launched Ethmozine, a class 1 anti-arrhythmic. He spent six years at Texas Biotechnology where he was closely involved in the development and approval of argatroban, a direct thrombin inhibitor. In 2000 Mr. McKinney was a member of the start-up executive team at Novazyme, a biotech involved in lysosomal storage disorders and which was subsequently acquired by Genzyme. At Genzyme he took on a Sr. VP and General Manager role and helped guide the integration of the Novazyme and Genzyme early phase research programs.

In 2004 Mr. McKinney began at Orexigen and in early 2005 became the Chief Operating Officer with involvement in all aspects of corporate fund raising including series B and C rounds, successful Initial Public Offering and follow-on secondary offering. He had primary oversight of a substantial IP portfolio resulting in 7 major patent allowances/issuances and was the co-inventor of several important patents underlying Contrave and Empatic formulations. Mr. McKinney also had direct responsibility of formulation development and manufacturing operations, Business Development, Corporate Communications, Reimbursement and Pricing Strategy and Biostatistics.

Mr. McKinney holds a Bachelor of Science in Microbiology (concentration in chemistry) from the University of Oklahoma and an M.B.A. in Global Management from the Thunderbird School of Global Management.

Neurovance Team Gregg Beloff
Chief Financial Officer, Danforth Advisors

Gregg applies more than 20 years of experience in the life science and technology industries ranging from venture-backed start-ups to publicly traded companies. Gregg co-founded Danforth Advisors a firm providing C-level and related financing support to life science companies. In his role at Danforth he has served as the CFO of multiple companies including Seres Health, Moderna, Syros, Syndax and Yumanity. Previously, he served as the CFO of ImmunoGen and RXi, two publicly traded biotechnology companies and three privately biotechnology held companies, including Archemix. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg graduated with a B.A. from Middlebury College and then subsequently received his J.D. from the University of Pittsburgh School of Law and M.B.A. from Carnegie Mellon University.

Neurovance TeamWilliam T. Pappafotopoulos, M.B.A.
Chief Accounting and Administrative Officer

Mr. Pappafotopoulos has been President and CEO of the Milton Financial Group, which he founded in 1985 and which serves venture capital, bioscience and financial firms, among others. Prior to forming the Milton Financial Group, Mr. Pappafotopoulos held financial, accounting and management positions in Fortune 100 companies, including Johnson & Johnson and Raytheon, and in the government, at the Internal Revenue Service. Mr. Pappafotopoulos received a B.S. in Accounting from Salem State University and an M.B.A. from Suffolk University.

 

Neurovance Team Catherine O’Brien
Director, Clinical Operations

Catherine O’Brien brings to Neurovance over twenty years of clinical trial management working with five international pharmaceutical companies. Her experience gives her an in-depth understanding of all of the processes and people involved in the design, execution, reporting and publication of a successful clinical trial.

Prior to joining Neurovance, Catherine’s previous professional history includes the management of international Alzheimer’s trials for Elan, diabetic neuropathy, fibromyalgia and general anxiety disorder trials for Pfizer. Catherine graduated from Sligo Regional Technical College in Ireland with an advanced degree (National Diploma) in Environmental Science.

Board of Directors

Jeff Bailey (Executive Chairman)

Mr. Bailey has held executive and leadership positions in the pharmaceutical and diagnostic imaging fields for nearly 30 years. Recently, he had served as President and Chief Executive Officer of Lantheus Medical Imaging Inc., until he retired in August 2015. Mr. Bailey had previously served as Chief Operating Officer of Fougera Pharmaceuticals and Chief Commercial Officer for King Pharmaceuticals. He was also President and General Manager of the northwest operating unit team at Novartis Pharmaceuticals. Earlier, he held commercial leadership positions at Johnson & Johnson, and he was national sales director for the Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Mr. Bailey earned a business degree from Rutgers University in New Jersey.

Brian GoffBrian Goff

Mr. Goff brings over 25 years of pharmaceutical leadership experience to Neurovance. Mr. Goff previously was President of the Hematology Division of Baxalta (a 2015 spin-out of Baxter Healthcare). During Mr. Goff’s leadership in that position, he generated significant growth of the hemophilia business and led the launch of several key rare disease products. Prior to joining Baxter in 2012, Mr. Goff was Vice President and Head of Novartis Pharmaceuticals’ multi-billion-dollar Primary Care business. Previously at Novartis’ Swiss headquarters, he led the global marketing of their flagship cardiovascular brand, and he spent 14 years in a variety of commercial leadership positions at Johnson & Johnson – including 10 years in CNS disorders.

Mr. Goff was awarded the Healthcare Businesswomen’s Association Mentor of the Year in 2014, and in July, 2016, he was named to the PharmaVoice list of 100 Most Inspiring Leaders in Life Sciences. He has a B.A. in Economics from Skidmore College and an M.B.A. from the Wharton School of Business.

Neurovance Board of DirectorsCampbell Murray, M.D. Novartis Venture Funds

Dr. Murray has been Chairman of the Neurovance sibling company Euthymics since 2010 and is a Managing Director of the Novartis Venture Funds in Cambridge, MA, USA. Prior to joining the venture fund in 2005, he worked at the Novartis Institutes for BioMedical Research as the director of special projects reporting to the president & CEO. Dr. Murray is a New Zealand trained physician, Kauffman Fellow and holds an M.B.A. from Harvard Business School and an M.P.P. (public policy) from the John F. Kennedy School of Government where he was a Knox Fellow and Rotary Ambassadorial Scholar. Dr. Murray serves as a director on the boards of Aerpio Therapeutics, ­Alios BioPharm, Euthymics Biosciences, Galera, ImaginAB, Neurovance and Tokai Pharmaceuticals.

Neurovance Board of DirectorsPaul Weiss, Ph.D., Venture Investors

Dr. Weiss joined Venture Investors in 2006 as a Managing Director, and focuses on making Healthcare investments. Dr. Weiss has over 20 years of operating experience in the biotech and pharmaceutical industries. He previously was President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma Solutions). Before joining Gala, he served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a biotechnology company that completed its IPO during his tenure, and was subsequently acquired by Johnson & Johnson. Earlier in his career, Dr. Weiss worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals, (now Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs, a division of American Home Products, and Director of Operations for Columbia Research Labs (Nasdaq: COB), a small, publicly held company that focuses on women’s health. Dr. Weiss is currently a member of the Boards of Directors for Aerpio Therapeutics, Akebia Therapeutics, Euthymics Bioscience, Mithridion, and ProCertus BioPharm (also acting President and CEO). He is an observer at Tissue Regeneration Systems and Inviragen. Dr. Weiss also serves on the Board of Directors for Tamir Biotechnology (formerly Alfacell Corporation, Nasdaq: ACEL). He received a B.S. in Biochemistry with honors from Carleton University-Ottawa, Ontario, a Ph.D. in Biochemistry and an M.B.A. from the University of Wisconsin-Madison, where he also worked as a postdoctoral research associate.

Neurovance Board of DirectorsDaniel R. Omstead, Ph.D., Tekla Capital Management

Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of Tekla Healthcare Investors, Tekla Lifesciences Investors and Tekla Healthcare Opportunities Fund, three NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development-stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

Neurovance Board of DirectorsBrigitte Smith, M.B.A., GBS Venture Partners

Ms. Smith co-founded GBS Partners in 1997 where she serves as managing partner. She has twenty years’ experience in venture capital, business strategy and start-up company operations. Ms. Smith has been investing and managing investments for GBS’s $450 million of life science specialized venture capital funds for more than 17 years. She serves on the board of GBS portfolio companies AirXpanders Inc, Endoluminal Sciences Pty Ltd, Neuromonics Pty Ltd, Proacta Inc, Vivive Inc, and Neurovance/Euthymics. Ms. Smith was the founding investor and chair of Pharmaxis Pty Ltd. Prior to founding GBS, she worked in the US and Australia in operating roles with early stage technology based companies, and at Bain & Company as a strategic management consultant. Ms. Smith earned a B.Chem.Eng. (Honours) degree from the University of Melbourne, and as a Fulbright Scholar completed a M.B.A. (Honours) from the Harvard Business School and a M.A.L.D. from the Fletcher School of Law and Diplomacy, both in Boston, USA.

Neurovance Board of DirectorsTimothy Barberich, B.S.Chem.

Mr. Barberich is the founder and former president, chief executive officer and chairman of Sepracor Inc., a publicly traded pharmaceutical company based in Marlborough, Massachusetts which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and was president and chief executive officer through 1999 when he also became chairman. He also serves on the boards of HeartWare, BioSphere Medical, Gemin X Biotechnologies and Resolyx Pharmaceuticals. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets. Mr. Barberich is a graduate of Kings College. He holds a Bachelors of Science degree in Chemistry.

Management Team

Jeff Bailey
Chairman and Chief Executive Officer 

Brian Goff
Chief Operating Officer

Anthony McKinney, M.B.A.
Founder and Chief Development Officer

Gregg Beloff
Acting Chief Financial Officer, Danforth Advisors

William T. Pappafotopoulos, M.B.A.
Chief Accounting and Administrative Officer

Catherine O’Brien
Director, Clinical Operations

Board of Directors

Jeff Bailey
(Executive Chairman)

Brian Goff

Campbell Murray, M.D.
Novartis Venture Funds

Paul Weiss, Ph.D.
Venture Investors

Daniel R. Omstead, Ph.D.
Tekla Capital Management

Brigitte Smith, M.B.A.
GBS Venture Partners

Timothy Barberich